Similar Posts
Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
RapidRatings’ James Gellert: Boeing declines in financial health rating
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email The Exchange James Gellert, RapidRatings executive chair, joins ‘The Exchange’ to discuss the financial health of Boeing, shipping companies, and more. 03:24 2 hours ago
Tax policy on the ballot: Where each 2024 presidential candidate stands on taxes
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Erica York, Tax Foundation senior economist, joins ‘Squawk Box’ to discuss the foundation’s tax policy tracker, where each 2024 presidential candidate stands on taxes, and more.
The S&P 500 will continue to meet resistance around the 4,800 level, says JPMorgan’s Jason Hunter
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Closing Bell Jason Hunter, JPMorgan head of technical strategy, joins ‘Closing Bell’ to discuss key levels to watch in the current market momentum. 02:30 6 minutes ago
Taiwan: the world’s new whiskey capital?
The results are in, and Taiwan’s Kavalan distillery has the best single-malt whiskey in 2015.
We’ve seen 18% year-over-year volume growth driven by e-commerce, says Payoneer CEO John Caplan
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Closing Bell: Overtime John Caplan, Payoneer CEO, joins ‘Closing Bell Overtime’ to talk consumer spending behavior heading into 2024. 03:17 Fri, Dec 29 20236:13 PM EST
